Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 17436410
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

  2005cited by this paper
• Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

  2004cited by this paper
• Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.

  2004cited by this paper
• Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer.

  2003cited by this paper
• Gefitinib (Iressa) trials in non-small cell lung cancer.

  2003cited by this paper
• Changes in Circulating VEGF Levels in Relation to Clinical Response during Chemotherapy for Metastatic Cancer

  2003cited by this paper
• Angiogenesis and apoptosis.

  2003cited by this paper
• Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients.

  2002cited by this paper
• Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer.

  2002cited by this paper
• Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis

  2002cited by this paper
• Human vascular endothelial growth factor B: Characterization of recombinant isoforms and generation of neutralizing monoclonal antibodies

  2002cited by this paper
• Clinical implications of circulating angiogenic factors in cancer patients.

  2001cited by this paper
• Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.

  2001cited by this paper
• Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.

  2000cited by this paper
• Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?

  2000cited by this paper
• Increased Blood Vascular Endothelial Growth Factor Levels in Patients with Acute Myocardial Infarction

  2000cited by this paper
• Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Cellular predictive factors for the drug response of lung cancer.

  2000cited by this paper
• Expression of matrix metalloprotease-2-cleaved laminin-5 in breast remodeling stimulated by sex steroids.

  1999cited by this paper
• High pre‐treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small‐cell lung cancer

  1998cited by this paper
• Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy.

  1998cited by this paper
• Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood.

  1998cited by this paper
• Revisions in the International System for Staging Lung Cancer.

  1997cited by this paper
• Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

  1995cited by this paper
• Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy.

  1992cited by this paper

• The influence of selected polymorphisms in matrix metalloproteinases on response to treatment and disease progression in patients with mesothelioma

  2019cites this paper
• Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma

  2019cites this paper
• Impact of Adjuvant Anthracycline‐Based and Taxane‐Based Chemotherapy on Plasma VEGF Levels and Cognitive Function in Breast Cancer Patients: A Longitudinal Study

  2018cites this paper
• Expression and survival significance of B-cell-specific Moloney murine leukemia virus integration site 1 and matrix metalloproteinase-9 in non-small-cell lung cancer

  2016cites this paper
• Roles of microsomal prostaglandin E synthase-1 in lung metastasis formation in prostate cancer RM9 cells.

  2014cites this paper
• Angiogenesis and Lung Cancer

  2011cites this paper
• Peripheral Blood Based Discrimination of Ulcerative Colitis and Crohn’s Disease from Non-IBD Colitis by Genome-Wide Gene Expression Profiling

  2011cites this paper
• An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity

  2011cites this paper
• Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

  2010cites this paper
• p53 dysfunction by xeroderma pigmentosum group C defects enhance lung adenocarcinoma metastasis via increased MMP1 expression.

  2010cites this paper
• Tumor and Stem Cell Biology p 53 Dysfunction by Xeroderma Pigmentosum Group C Defects Enhance Lung Adenocarcinoma Metastasis via Increased Mmp 1 Expression

  2010cites this paper
• Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

  2010cites this paper
• American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

  2010cites this paper
• 美国临床肿瘤学会Ⅳ期非小细胞肺癌化疗的临床实践指南更新

  2010cites this paper
• Clinical Practice Guideline Update on Chemotherapy for Stage IV Non – Small-Cell Lung Cancer

  2009cites this paper
• Deep depletion of abundant serum proteins reveals low‐abundant proteins as potential biomarkers for human ovarian cancer

  2009cites this paper
• Gene expression analysis of endobronchial epithelial lining fluid in the evaluation of indeterminate pulmonary nodules.

  2009cites this paper
• Presurgical serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in oral squamous cell carcinoma.

  2009cites this paper
• Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer

  2009cites this paper
• American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.

  2009cites this paper
• VEGF in patients with non-small cell lung cancer during combination chemotherapy of carboplatin and paclitaxel.

  2009cites this paper
• Putative functional polymorphisms of MMP9 predict survival of NSCLC in a Chinese population

  2009cites this paper
• Molecular and pathological signatures of epithelial–mesenchymal transitions at the cancer invasion front

  2008cites this paper